Dissertations / Theses: 'Pharmaceutical biotechnology industry'

1

Alimov, Azizjon. "Innovations, real options, risk and return : evidence from the pharmaceutical and biotechnology industries /." view abstract or download file of text, 2007. http://proquest.umi.com/pqdweb?did=1421619401&sid=1&Fmt=2&clientId=11238&RQT=309&VName=PQD.

Full text

Abstract:

Thesis (Ph. D.)--University of Oregon, 2007.
Typescript. Includes vita and abstract. Includes bibliographical references (leaves 109-114). Also available for download via the World Wide Web; free to University of Oregon users.

APA, Harvard, Vancouver, ISO, and other styles

2

Nel, Izak Bartholomeus Jacques. "The relationship between global pharmaceutical companies and the biotechnology industry in South Africa : implications for an emerging biotechnology industry in South Africa." Thesis, Stellenbosch : Stellenbosch University, 2003. http://hdl.handle.net/10019.1/53672.

Full text

Abstract:

Mini-study project (MBA)--University of Stellenbosch, 2003.
ENGLISH ABSTRACT: This report reviews the global and South African pharmaceutical and biotechnology industries and provides an overview of the changes taking place within these two industries. It highlights the impact this relationship will have on a developing South African biotechnology industry. Since the 1980s the pharmaceutical industry has experienced phenomenal growth in sales and profits. By the mid 1990s drug sales exceeded USD250 billion. Today the pharmaceutical industry is dominated by multi-national corporations with extensive R&D budgets, widespread use of trademarks and patents and complex commercial process technology. However they face threats from depleted product pipelines, patent expiry on billion dollar drug products, generic competition, increases in drug approval times, costs and price pressures. The entrepreneurial biotechnology industry promises to solve a number of the pharmaceutical industry's problems. In recent years biotechnology companies proved more effective in the development of new molecular entities. They promise individualised therapeutics, novel and more efficacious drug discovery and development of preventative treatments. However the decrease in equity financing after 2001 left almost 40% of biotechnology companies with less than 1 year of R&D funding. The industry experienced losses again in 2002 and the world is divided over the ethical, environmental and economic implications of biotechnological applications. The biotechnology and pharmaceutical industries have a symbiotic but antagonistic relationship. The change in this relationship will hugely affect South Africa's ideals of developing a biotechnology industry. Various diseases plague South Africa including HIV/AIDS, TB, obesity, diabetes, hypertension and infective diseases. These diseases will have a huge impact on South Africa's society. Yet only 10% of global R&D funding is committed to third world diseases and existing drugs and treatments are either not effective or too expensive for developing countries. It is in this situation that biotechnology and the development of a biotechnology industry could playa major role in alleviating South Africa's health burden. South Africa is already capable in first generation biotechnology, but third generation applications holds the most promise. Developing countries face various obstacles and challenges, but all boast well for South Africa. The government has committed R400 million (over a three year period) to utilize South Africa's biotechnology potential. Further, the country has highly skilled researchers, indigenous plant and animal species, a diverse population and a favorable exchange rate (low R&D costs).
AFRIKAANSE OPSOMMING: Die projek ondersoek beide die globale en Suid Afrikaanse farmaseutiese en biotegnologie industrieë. Verder word die veranderinge wat plaasvind in die industrieë onder die soeklig geplaas. Die projek beklemtoon die impak wat die verhouding sal hê op 'n ontwikkelende biotegnologie industrie in Suid Afrika. Die farmaseutiese industrie het sedert die 1980s dubbel syfer groei getoon in omsete en wins. Teen die middel 90's het verkope van farmaseutiese middels US$250 miljard wêreldwyd oorskry. Vandag word die farmaseutiese industrie oorheers deur multi-nasionale korporasies met omvattende navorsing en ontwikkelings begrotings, algemene gebruik van handelsmerkte, patente en komplekse proses-tegnologieë. Ten spyte hiervan word die industrie bedreig deur leë produksie-lyne, verval van patente, miljard dollar farmaseutiese produkte, generiese kompetisie, verlengde produk-goedkeurings periodes en prys-mededinging. Die biotegnologie industrie met sy innoveerende eienskappe beloof om verskeie van die farmaseutiese industrie se probleme op te los. Onlangs het biotegnologie maatskappye getoon dat hulle meer effektief is in die ontwikkeling van nuwe molekulêre eenhede. Biotegnologie beloof nuwe en meer effektiewe produk-ontwikkeling asook beter individuele terapieë en voorkomende behandelings. Die industrie staar finansiële krisisse in die gesig. Slegs 40% van biotegnologie maatskappye het voldoende navorsing en ontwikkelings-kapitaal tot 2004. Dit is hoofsaaklik as gevolg van 'n afname in eienaars-finansiering na 2001. Die industrie as 'n geheel het weereens 'n verlies gelei in 2002 en die wêreld is verdeeld oor die etiese, omgewings en ekonomiese implikasie van biotegnologiese toepassings. Die biotegnologie en farmaseutiese industrieë het 'n simbiotiese maar tog vyandige verhouding. 'n Verandering in die verhouding gaan Suid Afrika se ideale om 'n biotegnologie industrie te skep grootliks beïnvloed. Suid Afrika gaan gebuk onder verskeie siektes insluitende MIVNIGS, TB, vetsugtigheid, diabetes, hipertensie en infeksie siektes. Hierdie siektes het 'n groot impak op Suid Afrika se samelewing. Tog word slegs 10% van die globale navorsings en ontwikkelingsfondse aangewend om 'n oplossing te vind vir derdewêreld siektes. Verder is bestaande produkte en behandelings oneffektief of onbekostigbaar vir ontwikkelde lande. Dit is in sulke gevalle waar biotegnologie en die ontwikkeling van 'n biotegnologie industrie 'n groot rol kan speel in die verligting van Suid Afrika se gesondheids-las. Suid Afrika is vaardig in eerste-generasie biotegnologie, maar wêreld wyd hou derde generasie biotegnologie die meeste belofte in. Die tegnologie is tot op hede onderbenut in Suid Afrika. Ontwikkelende lande staar verskeie uitdagings in die gesig, maar Suid Afrika het talle sterk punte. Die regering het R400 miljoen (oor 'n drie jaar periode) beskikbaar gestel vir die ontwikkeling van Suid Afrika se biotegnologie potensiaal. Die land beskik ook oor navorsers van hoogstande gehalte, onbenutte inheemse plante en dier spesies, 'n diverse populasie en 'n gunstige wisselkoers (lae navorsings en ontwikkelings kostes).

APA, Harvard, Vancouver, ISO, and other styles

3

Gretton, Linda Burak. "The rhetorical helix of the biotechnology and pharmaceutical industries strategies of transformation though definition, description and ingratiation /." Greensboro, N.C. : University of North Carolina at Greensboro, 2007. http://libres.uncg.edu/edocs/etd/1435/umi-uncg-1435.pdf.

Full text

Abstract:

Thesis (Ph.D.)--University of North Carolina at Greensboro, 2007.
Title from PDF t.p. (viewed Oct. 22, 2007). Directed by Nancy Myers; submitted to the Dept. of English. Includes bibliographical references (p. 209-228).

APA, Harvard, Vancouver, ISO, and other styles

4

Vazquez, Toro Guillermo J. "Patent Quality And Company Performance| A Sample within the USA Biotechnology and Pharmaceutical Industry." Thesis, Inter-American University of Puerto Rico (Puerto Rico), 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3577982.

Full text

Abstract:

This Dissertation investigates the relationship between patent quality and company performance for a sample from the US Biotechnology and Pharmaceutical Industry. The methodology devised comprehensively examines patent worth (patent’s references), patent protection (claims and family patents) and patent quality (references, claims and family patents) to determine their implications on firm leverage (SE, TA), profits (ROE, ROA), and market value (B/M, MCap). The selected sample comprises 1,536 companies, and 285,000 patents from 1999 to 2009. The results show that total revenue just responds to changes in R&D; intensity, and patenting intensity. A 10 percent increase in patent value results in a corresponding increase rate on the market capitalization index for the full sample and a 14 percent increase for the chemicals and allied products group (SIC 28). Increases (10%) in patent protection and quality present average increases of 15 percent on market capitalization for the full sample and 8 percent for the chemicals and allied products group (SIC 28). The medical devices group (SIC 38) results suggest that Mcap increases 10 percent by the same increase in patent value index. Patent protection and quality increases (10%) suggest an average 8 percent increase in Mcap. Results suggest that profits, leverage and market indices respond differently to 10 percent increases in patent value, patent protections and patent quality. The aforementioned effects suggest that the qualitative indexes follow company related market activities and business valuations for the chemical and allied products, and medical devices industrial sectors.

APA, Harvard, Vancouver, ISO, and other styles

5

Otieno, Charles J. "Analysis of strategic alliance deals in the global CNS industry /." Burnaby B.C. : Simon Fraser University, 2006. http://ir.lib.sfu.ca/handle/1892/2741.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Houston, Chad Allen. "Biotechnology valuation an examination of the drug development pipeline and board of director composition /." View electronic thesis (PDF), 2009. http://dl.uncw.edu/etd/2009-3/r1/houstonc/chadhouston.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pavúk, Šimon. "Aplikácia investičnej analýzy na biotechnologicko- farmaceutický sektor." Master's thesis, Vysoká škola ekonomická v Praze, 2010. http://www.nusl.cz/ntk/nusl-76239.

Full text

Abstract:

The principal aim of this thesis is to describe methods of fundamental analysis of three major companies from sectors of Biotechnology and Pharmaceuticals, namely Johnson & Johnson, Pfizer and Amgen. Among used methods we are able to find 2 -- stage discounted cashlow models Free-cashflow-to-equity FCFE and Free-cashflow-to-firm FCFF, Gordon's dividend discount model a relative valuation methods using P/E, P/BV and P/S. Descriptive part of this thesis describes legal and regulatory environment, which has significant impact on the development process of new innovative drugs and therapies. Further it sets investment recommendations and looks closer at investment opportunities in biotechnological companies.

APA, Harvard, Vancouver, ISO, and other styles

8

Possnert, Oliver, and Adam Schön. "A case study research of asymmetrical relationshipsbetween service providers and emerging companieswithin the healthcare industry." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-353334.

Full text

Abstract:

This master thesis report aims to highlight the importance ofinterorganizational relationships between experienced serviceproviders and emerging biopharmaceutical (EBP) companies within theSwedish healthcare industry. A shift in innovation strategiesregarding new pharmaceutical- and medical device products hasprompted a paradigm shift within a complex industry wherecollaborations between organisations has become increasinglycrucial. With a better understanding of how these companiesoperates, increased collaboration efforts could result in a fasterand more precise product development with new products reaching themarket improving the health for people around the world. In order toallow experienced service providers to enhance services towards EBPcompanies, a fundamental understanding of how decision makers withinthese EBP companies prefer to conduct relationships is needed. Wehave examined relationship preferences of EBP companies byconducting a qualitative case study through 14 interviews withdecision makers combined with a quantitative conjoint analysis.Eight factors was identified as important for when EBP companiesdecide to engage with a service provider: cost behavior,professional competence, adaptability, communication, personalrelationship, stability, EBP insight and size. The factorsadaptability, personal relationship, cost and size were used in theconjoint analysis to determine their relative importance which showthat adaptability and cost behavior was of the largest importance.With descriptions of each factor, we have provided a meaningfulguide to action of how to address these factors as a serviceprovider. The relationships is largely investigated as relationshipsbetween contract research organizations (as service providers) andEBP companies, but we have created a framework applicable forservice providers within the healthcare industry in general.

APA, Harvard, Vancouver, ISO, and other styles

9

Rybička, Miloš. "Analýza vybraných průmyslových sektorů v ČR a v SRN a komparace jejich konkurenceschopnosti jako podklad pro strategická rozhodování." Master's thesis, Vysoká škola ekonomická v Praze, 2012. http://www.nusl.cz/ntk/nusl-162363.

Full text

Abstract:

The goal of this Masters Thesis is to analyze three selected industry sectors in the Czech Republic and in Germany. Concretely the industries in focus are engineering, motor vehicle manufacturing and finally pharmacy along with bio- and nanotechnology. Furthermore, factors limiting but also supporting the industry development are identified and described in the Thesis. In the Thesis, analytical instruments will be used, especially the SWOT analysis and benchmarking. The Thesis is mainly intended for managers, employees, consultants and all other direct or indirect interest groups of both Czech and German industry companies and their suppliers but also for potential investors who are deciding whether to enter a market in the CEE region.

APA, Harvard, Vancouver, ISO, and other styles

10

Larsen, David Mark. "The discursive function and the embedding of capitalism : British state policy on the pharmaceuticals and biotechnology sector." Thesis, University of Cambridge, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.608970.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Volk, Jennifer M. "Do Investors View Excess Capacity as a Determinant of Mergers and Acquisitions in the Pharmaceutical and Biotechnology Industry?" Scholarship @ Claremont, 2010. http://scholarship.claremont.edu/cmc_theses/15.

Full text

Abstract:

I examine investors’ reaction to the announcement of mergers and acquisitions in the pharmaceutical and biotechnology industry from 2002 to 2008. Over this period, investors anticipate the announcements, as demonstrated by the fact that the cumulative abnormal returns are not statistically significant. In addition, I test to determine the effect of excess capacity on investors’ reactions. From 2002 to 2004, investors do not recognize acquisitions as a response to excess capacity, as the excess capacity measures utilized have no effect on the size of the cumulative abnormal return. From 2005 to 2008, however, excess capacity measures have a positive effect on cumulative abnormal return, indicating that investors started to recognize the threat of excess capacity and acquisitions as a response to that threat.

APA, Harvard, Vancouver, ISO, and other styles

12

Rasmussen, Bruce. "Creating and capturing value in the biopharmaceutical sector." full-text, 2008. http://eprints.vu.edu.au/1946/1/Bruce_Rasmussen_PHD_2009.pdf.

Full text

Abstract:

This study addresses the ongoing implications of the realignment of the pharmaceutical industry knowledge base – from small molecule methods to new biomedical technologies – for the competitive positions of traditional pharmaceutical companies and biopharmaceutical start-ups. The theoretical approach draws on the modern theory of the firm and related concepts, to define and develop the concept of the business model. This is employed to guide the empirical analysis, which utilises a combination of data analyses and case studies based on several sources, including detailed company reports and alliance databases. The thesis analyses how the pharmaceutical companies have successfully adjusted their business models to meet the challenge of biotechnology and so retain their powerful position in the industry. Central to this has been the breadth and depth of knowledge transfer through alliance formation. Not only has this been critical to the adjustment process for the large pharmaceutical companies but also for the development of the many biopharmaceutical start ups. Nonetheless the business models of these smaller companies have many weaknesses, which have led to the erosion of the value of their initial strategic assets. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. This has been captured disproportionately by a handful of large fully integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical firms.

APA, Harvard, Vancouver, ISO, and other styles

13

Rasmussen, Bruce. "Creating and capturing value in the biopharmaceutical sector." Thesis, full-text, 2008. https://vuir.vu.edu.au/1946/.

Full text

Abstract:

This study addresses the ongoing implications of the realignment of the pharmaceutical industry knowledge base – from small molecule methods to new biomedical technologies – for the competitive positions of traditional pharmaceutical companies and biopharmaceutical start-ups. The theoretical approach draws on the modern theory of the firm and related concepts, to define and develop the concept of the business model. This is employed to guide the empirical analysis, which utilises a combination of data analyses and case studies based on several sources, including detailed company reports and alliance databases. The thesis analyses how the pharmaceutical companies have successfully adjusted their business models to meet the challenge of biotechnology and so retain their powerful position in the industry. Central to this has been the breadth and depth of knowledge transfer through alliance formation. Not only has this been critical to the adjustment process for the large pharmaceutical companies but also for the development of the many biopharmaceutical start ups. Nonetheless the business models of these smaller companies have many weaknesses, which have led to the erosion of the value of their initial strategic assets. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. This has been captured disproportionately by a handful of large fully integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical firms.

APA, Harvard, Vancouver, ISO, and other styles

14

Delagustin, Maria Gabriele. "Caracterização e avaliação da estabilidade do ácido lactobiônico e de diferentes lactobionatos produzidos por Zymomonas mobilis visando à utilização na área farmacêutica." reponame:Repositório Institucional da UCS, 2016. https://repositorio.ucs.br/handle/11338/1796.

Full text

Abstract:

O ácido lactobiônico e seus sais (lactobionatos), compostos que apresentam aplicações na área farmacêutica, foram obtidos via ação do complexo enzimático glicose-frutose oxidorredutase (GFOR)/gliconolactonase (GL) - presente no periplasma de células da bactéria Zymomonas mobilis - imobilizado em alginato de cálcio. Nas reações catalisadas por este sistema enzimático, o pH do meio deve ser controlado em valores ligeiramente ácidos. Para este fim, foram empregados NaOH, KOH ou Ca(OH)2 e, como consequência, os respectivos sais foram formados. O estudo da cinética de formação dos lactobionatos de sódio, potássio e cálcio e do próprio ácido lactobiônico foi seguido das etapas de purificação, caracterização e avaliação da estabilidade físico-química, visando à potencial utilização destes compostos na área farmacêutica. Em ensaios de bioprodução dos lactobionatos de sódio, potássio e cálcio, foram obtidos rendimentos de 74, 77 e 84%, respectivamente. Em bateladas sucessivas de bioconversão, totalizando 96 h de uso do biocatalisador, rendimentos de 80 e 56 % em lactobionatos de cálcio e de potássio foram atingidos. Na etapa de purificação dos sais, foram alcançados teores de pureza de aproximadamente 95%, sendo então procedida a caracterização dos compostos por cromatografia líquida de alta eficiência, espectrometria de massas e RMN de 13C. Nos estudos de estabilidade acelerada, de longa duração e degradação forçada, os lactobionatos de sódio, potássio e cálcio obtidos nos ensaios de bioconversão conduzidos em maior volume reacional, foram inicialmente purificados e, então, comparados frente ao ácido lactobiônico, obtido por troca iônica a partir do lactobionato de sódio, e com o ácido lactobiônico comercial (Sigma-Aldrich). Nos testes de estabilidade acelerada e de longa duração, foi constatada a estabilidade de todos os compostos por até seis meses quando expostos a 30 e 40oC e 75% de umidade relativa. Por outro lado, a presença da lactobionolactona foi identificada nas amostras dos compostos na forma ácida. Com relação aos testes de degradação forçada, os lactobionatos de sódio, potássio, e cálcio e o ácido lactobiônico se mostraram estáveis frente à exposição a soluções ácidas e alcalinas e às temperaturas avaliadas. Contudo, observou-se degradação no tratamento com solução oxidativa, com cinética de degradação de ordem zero para os sais e de segunda ordem para o ácido lactobiônico. Elevadas concentrações de produtos - lactobionatos de sódio, potássio e cálcio - foram atingidas com a utilização do sistema GFOR/GL imobilizado em alginato de cálcio. Considerando o conjunto de informações obtido, quanto à caracterização físico-química dos compostos produzidos, foi demonstrada a estabilidade frente aos diferentes parâmetros avaliados atendendo aos requisitos mínimos legais para sua aplicação na área farmacêutica.
Submitted by Ana Guimarães Pereira (agpereir@ucs.br) on 2017-03-09T14:08:07Z No. of bitstreams: 1 Dissertacao Maria Gabriele Delagustin.pdf: 3945297 bytes, checksum: e76bd0d7370a803326a4ebd56fb7e6b1 (MD5)
Made available in DSpace on 2017-03-09T14:08:07Z (GMT). No. of bitstreams: 1 Dissertacao Maria Gabriele Delagustin.pdf: 3945297 bytes, checksum: e76bd0d7370a803326a4ebd56fb7e6b1 (MD5) Previous issue date: 2017-03-09
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES.
Lactobionic acid and its salts (lactobionate) are substances that have several applications in pharmaceutical area. These products were obtained by enzymatic complex glucose-fructose-oxidoreductase (GFOR)/gluconolactonase (GL) present in the periplasm of Zymomonas mobilis cells that were immobilized in calcium alginate. In the reactions catalyzed by this enzyme system, the medium pH must be controlled at slightly acid values. For this purpose, NaOH, KOH, or Ca(OH)2 were used and as a result the respective salts were formed. The kinetic study on the formation of sodium, potassium and calcium lactobionate and lactobionic acid itself was followed by the steps of purification, characterization and evaluation of the physicochemical stability, aiming the potential use of these compounds in the pharmaceutical area. In the assays for the bioproduction of sodium, potassium or calcium lactobionates, yields of 74, 77 and 84% were obtained, respectively. In repeated bioconversion batches, totalizing 96 hours of use of the biocatalyst, yields of 80 and 56% were attained for calcium and potassium lactobionate. In the salts purification step, purity levels of approximately 95% were achieved, and subsequently these compounds were characterized by high performance liquid chromatography, mass spectrometry, and C13 NMR. In the studies of accelerated, long term and forced degradation stability, the production of sodium, potassium and calcium lactobionate was carried out at higher reaction volume. The products were purified and then evaluated together with lactobionic acid that was obtained by ion-exchange from sodium lactobionate, and with a commercial lactobionic acid (Sigma-Aldrich). In the accelerated and long term stability tests, it was demonstrated the stability of all compounds when exposed to 30 and 40oC and of 75%of relative humidity for up to six months. On the other hand, the presence of lactobionolactone was identified in samples of compounds in the acid form. With respect to the forced degradation tests, sodium, potassium and calcium lactobionates and lactobionic acid have shown to be stable after exposing to both acidic and alkaline solutions and the temperatures evaluated. However, degradation was observed in the treatment with oxidative solution, with a zero-order degradation kinetics for the salts forms and second-order for lactobionic acid. High concentrations of products - sodium, potassium and calcium lactobionate - were achieved by using the Ca-alginate immobilized GFOR/GL complex. Considering the set of information obtained in regarding to physicochemical characterization, it was demonstrated the high stability of these compounds in front of different parameters evaluated, endorsing the legal minimum requirements for their application in the pharmaceutical area.

APA, Harvard, Vancouver, ISO, and other styles

15

Guedri, Zied. "Performance variations among strategic group members in the pharmaceutical industry : an examination of individual sustainable growth capabilities, 1995-1997." Thesis, Connect to online version, 1998. http://0-wwwlib.umi.com.mercury.concordia.ca/cr/concordia/fullcit?pMQ39083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Schmidt, Stefan. "Merger and acquisition between small biotech and large pharmaceutical companies - a winning combination? : Case study on the acquisitions of CAT by AstraZeneca and Abgenix by Amgen; MBA thesis in marketing." Thesis, University of Gävle, Department of Business Administration and Economics, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:hig:diva-3261.

Full text

Abstract:

This study aims at introducing and describing a novel multi parameter analysis method to identify potential acquisition targets and to qualitatively and quantitatively evaluate the overall match between a target company and its acquirer. The method was tested with two recent real cases involving each an antibody based biotech company and a large fully integrated pharmaceutical company. The model was validated by comparing two independent antibody companies against the real cases, testing if they would have made better targets. It was found out that the in reality acquired companies scored highest, thus proving the validity of the method. One of the four potential targets got the highest scores for both acquirers. Consequently one of the acquired targets was only the second best match. The still independent companies would not have been better targets. The lowest scoring target company did get identical scores for both acquiring companies. Despite the proper prediction of targets, the scoring did not reveal the true underlying motives for the acquisitions, nor could significant parameters be identified to discriminate between target and non-target. This study adds a novel, valuable tool to the still limited arsenal of methods to qualitatively and quantitatively measure a match between target and acquirer solely based on publicly available data.

APA, Harvard, Vancouver, ISO, and other styles

17

Langer, Lynn Johnson. "How Scientist/Founders Lead Successful Biopharmaceutical Organizations: A Study of Three Companies." [Yellow Springs, Ohio] : Antioch University, 2008. http://www.ohiolink.edu/etd/view.cgi?acc_num=antioch1217337156.

Full text

Abstract:

Thesis (Ph.D.)--Antioch University, 2008.
"A dissertation submitted to the Ph.D. in Leadership & Change Program of Antioch University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May 2008."--from the title page. Title from PDF t.p. (viewed July 30, 2008). Advisor: Alan Guskin, Ph.D.. Keywords: biotechnology, biopharmaceutical, leadership, founder, success, management, case study Includes bibliographical references (p. 207-218).

APA, Harvard, Vancouver, ISO, and other styles

18

Guezguez, Hella. "Innovations et alliances stratégiques : une analyse en termes d'intégration des connaissances appliquée à l'industrie bio-pharmaceutique." Phd thesis, Université Nice Sophia Antipolis, 2013. http://tel.archives-ouvertes.fr/tel-00932410.

Full text

Abstract:

En prenant pour point de départ l'émergence de technologies nouvelles, ce travail s'interroge sur la capacité des acteurs d'une industrie à réorganiser leurs bases de connaissances. Dans ce but, nous nous intéressons aux processus d'intégration des connaissances que nous définissons comme la recherche de complémentarité technologique dans les bases de connaissances des acteurs engagées dans des processus d'innovation. Dans un environnement technologique donné, larecherches de complémentarité technologique définit la recherche des combinaisons technologiques les plus productives. Deux angles de recherche sont ainsi privilégiés : les processus d'intégration intra-organisationnelle des connaissances et les processus d'intégration inter-organisationnelle des connaissances. Appliqué à l'étude des biotechnologies et de l'industrie pharmaceutique, ce travail de nature économétrique mobilisant des bases de données innovations, brevets et alliancesnous permet d'avancer deux principaux résultats. Dans le cadre des processus d'intégration intra-organisationnelle des connaissances, nous montrons que la recherche de complémentarité technologique est déterminée par la détention de connaissances fondamentales qui favorise la capacité des firmes à combiner leurs savoirs et par conséquent leur capacité à innover. Dans le cadre des processus d'intégration inter-organisationnelle des connaissances, nous montrons que la recherche de complémentarité technologique détermine le choix pour les acteurs d'une industrie de former une alliance stratégique et que cette recherche de complémentarité technologique évolue tout au long du cycle de vie de la technologie

APA, Harvard, Vancouver, ISO, and other styles

19

Kristoffersson, Michelle, and Christina Pettersson. "Outsourcing inom läkemedelsbranschen : Det faktiska utfallet." Thesis, Högskolan i Skövde, Institutionen för handel och företagande, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-13912.

Full text

Abstract:

Bakgrund: Outsourcing är inget nytt fenomen då transaktionskostnadsteorin formades 1937 som beskrev att företag bör vända sig till marknaden i de fall detta gynnade företaget ekonomiskt. Sedan dess har teorier kring outsourcing förändrats och i dag handlar outsourcing om att kunna fokusera på företagets kärnkompetens och vilka möjligheter och risker outsourcing medför. Läkemedelsbranschen har på senare år börjat outsourca forskning och produktutveckling, vilka ses som kärnprocesser. Det råder därför delade meningar om branschen faktiskt har en kärnprocess. Syfte: Syftet med denna uppsats är att förstå hur och varför läkemedelstillverkningsbranschen outsourcar, om de outsourcade processerna har koppling till företags kärnprocesser och hur outsourcing faktiskt påverkar företaget, både monetärt och icke-monetärt. Metod: Det empiriska materialet insamlades med både kvantitativ och kvalitativ metod. En enkätundersökning genomfördes för att få en generell bild av hur läkemedelstillverkningsbranschen outsourcar för att sedan genomföra tre intervjuer för att få djupare kunskap om varför företag gjort de angivna val kring outsourcing. De intervjuade företagen valdes ut genom ett typiskt urval där företag valdes som svarat utifrån vissa bestämda kriterier. Slutsats: Uppsatsen har belyst att den vanligaste processen att outsourca är tillverkning, men att även forskning och produktutveckling outsourcas till viss del. Detta berodde på att företag upplevde resurs- och kunskapsbrist inom de outsourcade processerna. Studien fann även att sambandet mellan anledningen till och utfallet av outsourcing var svagt. Däremot hamnade den ökade lönsamheten sist inom båda kategorierna. Det påvisades också att det är svårt att definiera en kärnprocess till branschen med anledning av den diversifiering som i dag karaktäriserar branschen. Däremot framkom produktutveckling som den vanligaste kärnprocessen inom företag, där det visade sig att företag inte tenderar att outsourca sin kärnprocess.
Background: Outsourcing is not a new phenomenon. Transaction cost theory was formed in 1937, which described that companies should transfer activities externally when this benefited companies financially. Since then, theories of outsourcing have changed and today, it has been switched to outsourcing of core competencies and a discussion of both opportunities and risks. In recent years the pharmaceutical industry has started to outsource their research and product development, which is considered a core process. Due to this there is a debate whether or not the industry has a core process. Purpose: The purposes of this thesis are to understand how and why the pharmaceutical manufacturing industry is outsourcing, how the outsourced processes relate to their core processes and how outsourcing affects the companies, both monetary and non-monetary. Method: The empirical evidence was gathered with both quantitative and qualitative methods. Firstly, a survey was conducted to get a general picture of how the pharmaceutical manufacturing industry outsources which was then followed by three interviews to gain an in-depth knowledge of why companies have made specified decisions regarding outsourcing. The companies were selected according to a number of specific criteria. Conclusion: The thesis has highlighted that manufacturing is the most common process of outsourcing, but also that research and product development is outsourced to some extent. This was due to the fact that companies experienced resource and knowledge shortage in the outsourced processes. The study also found that the relation between the reason and the outcome of outsourcing was weak. However, the increased profitability ended last in both categories. It was also found that it is difficult to define a core process within the industry due to the diversification that today characterizes the industry. On the other hand, product development appear to be the most common core process within companies, where it also shows that companies tend not to outsource their core process.

APA, Harvard, Vancouver, ISO, and other styles

20

Chan, Leong. "Developing a Strategic Policy Choice Framework for Technological Innovation: Case of Chinese Pharmaceuticals." PDXScholar, 2013. https://pdxscholar.library.pdx.edu/open_access_etds/1041.

Full text

Abstract:

With the growing trend of globalization and rapid development of high technologies, emerging economies face more challenges in technology development because they are chasing a fast-moving frontier. They need to identify global technology trends and adapt to local needs and capabilities. Strategies for technology development differ among countries at different developmental stages. In this research, a technology policy choice framework is developed to link prospective high-tech areas, technology development strategies, and various innovative resources. The research approach is to develop a hierarchical decision model (HDM) and apply the analytic hierarchical process (AHP). Experts are invited from diverse sources to provide a balanced perspective representing different stakeholders. This research focuses on the fast developing Chinese biopharmaceutical industry as a case study. The results of this research have identified thirteen prospective biotech areas that China should invest more resources for development. These technology areas include: recombinant therapeutic proteins, recombinant vaccines, monoclonal antibody technology, cell and tissue engineering, gene therapy, antisense therapy, RNAi, nanobiotechnology, synthetic biology, bioinformatics, pharmacogenetics, gene sequencing, and biotechnology diagnostics. For most of these technology areas, the results have indicated an imitative innovation strategy should be taken as a better strategy under current technological conditions in China. The research has further found that high-tech small-to-medium companies and multinational corporations are major innovation contributors in the Chinese biopharmaceutical sector. The research outcomes can serve as guidelines in resource allocation and policy making for technology development. Based on the overall research findings, policy-makers can apply more specific policy instruments to support innovation activities. Appropriate policy measures may help the country to construct an innovative ecosystem that can serve as the driving force for future technology development.

APA, Harvard, Vancouver, ISO, and other styles

21

Swarna, Kailash 1963. "The evaluation of system-wide financial incentives in pipeline decisions in the pharmaceutical and biotechnology industry : the paradox of R&D spend Vs. new drug approvals." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/72888.

Full text

Abstract:

Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management, 2012.
Cataloged from PDF version of thesis.
Includes bibliographical references (p. 98-102).
For several decades, the ascendancy of the Pharma & Biotech sector was largely driven by favorable macro-economic conditions combined with an astonishing level of innovation and a clear focus on addressing unmet medical needs. Significant R&D investments led to innovative drugs that changed clinical practice across multiple illnesses and contributed to an overall rise in life expectancy around the world. Unfortunately, this trend has not continued. Since the mid-90s', the approval of novel drugs has plummeted despite record levels of R&D investment. It is estimated that between 2000 and 2010, the top 10 global Pharma and Biotech companies have collectively invested over $500 Billion in R&D. In the same period, only about 150 novel drugs entered the market. This is partly explained by the fact that quick-wins have been harvested, and that further progress in treating grievous illness is harder to achieve. This is compounded by increasing concerns about the longterm safety of drugs and the conservative regulatory climate that has prevailed since 2000. In this challenging regulatory and cost environment, the basic economic model of the industry is now being questioned. In this work I review the recent financial performance of ten major global pharmaceutical companies, and the challenges faced by the industry in moving from a deterministic, blockbuster era to a more stochastic era defined by multiple unknowns.
by Kailash Swarna.
M.B.A.

APA, Harvard, Vancouver, ISO, and other styles

22

Costa, Magnólia Maria Almeida dos Santos. "I & D e inovação na indústria farmacêutica : o caso português." Master's thesis, Instituto Superior de Economia e Gestão, 1998. http://hdl.handle.net/10400.5/18810.

Full text

Abstract:

Mestrado em Economiae e Gestão de Ciência e Tecnologia
A evolução da indústria farmacêutica nas últimas décadas, embora integrando-se no quadro de desenvolvimento global da economia, preserva a sua própria autonomia, devido ao carácter eminentemente social, traduzível nos seus objectivos de combate à doença e à morte, bem como de busca progressiva do bem estar físico e psíquico da humanidade. E porque nesse domínio, nada é imutável, o grau crescente de exigência quanto a níveis de qualidade, de eficácia e de segurança no sector implica uma postura dinâmica e criativa do lado da oferta. Neste contexto, a I&D e a Inovação têm sido importantes motores da indústria farmacêutica, processos em que a dimensão imaterial predomina, influenciando o comportamento dos demais factores das actividades inovadoras. Assim, este estudo tem como âmbito a indústria farmacêutica, num contexto de globalização económica, com incidência nos vectores de l&D e de Inovação e como objectivo responder fundamentalmente a duas questões: i) Num sector em que a Inovação e a l&D são essenciais, como é o caso da indústria farmacêutica, saber qual a influência da procura, e designadamente a do consumidor final, no seu desenvolvimento; ii) na identificação do desempenho das empresas de pequena dimensão e das empresas de grande dimensão, quais as relações, de complementaridade ou de predominância, que se estabelecem entre elas no quadro da l&D e da Inovação farmacêuticas. Para responder a estas questões recorremos à revisão da literatura conhecida, que complementámos com a análise empírica de casos relativos a empresas farmacêuticas, nacionais e estrangeiras, implantadas em território português.
The evolution of the pharmaceutical industry in the last decades, although integrated in the general frame of economical development, preserves its own autonomy, owing to the eminent social nature of its objectives of action against desease and death and of progressivo search for human physical and psychic well-being. Because on this realm nothing is unchangeable, the growing dregree of exigency as to the leveis of quality, efficiency and security in the sector implies a dynamic and creative approach from the supply side. Therefore, Research and Development and Innovation have been important motors of the pharmaceutical industry, as processes where the immaterial dimension prevails and exerts influence upon the behaviour of the other factors related to the innovating activities. Consequently, the scope of the present work is the pharmaceutical industry, in a context of economical globalization, with emphasis on the R&D and Innovation vectors, being its main objective the answer to two fundamental questions: 1) In a sector where Innovation and R&D, are essential, as it is the case of the pharmaceutical industry, to know the influence that the demand, and particularly the final consummer, may exercise on its development; 2) when identifying the performance of small and big companies, what kind of complementary and/or predominance relations are established among them within the ambit of R&D and pharmaceutical innovation. In order to answer these questions, we proceeded to the re- examining of known literature, which we completed with the empirical analisys of cases related to pharmaceutical companies, both national and foreign, operating in Portugal.
info:eu-repo/semantics/publishedVersion

APA, Harvard, Vancouver, ISO, and other styles

23

史洪昊. "單克隆抗體在中國的發展現狀和未來趨勢." Thesis, University of Macau, 2012. http://umaclib3.umac.mo/record=b2590335.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Guimarães, Maria Celeste Neves. "Inovação aberta e vantagem competitiva: um estudo exploratório das indústrias farmacêuticas no Brasil." Universidade Presbiteriana Mackenzie, 2015. http://tede.mackenzie.br/jspui/handle/tede/670.

Full text

Abstract:

Made available in DSpace on 2016-03-15T19:26:29Z (GMT). No. of bitstreams: 1 Maria Celeste Neves Guimaraes.pdf: 3080204 bytes, checksum: d282f9abecffa0e8178b45631081ac10 (MD5) Previous issue date: 2015-12-08
Esta dissertação analisa a vantagem competitiva das indústrias farmacêuticas, segmento saúde humana Brasil, que adotam a inovação aberta. É um estudo de caráter exploratório e abordagem qualitativa descritiva. Qual é a contribuição da inovação aberta para a vantagem competitiva da indústria farmacêutica foi a pergunta de pesquisa. Identificar a prática da inovação nas empresas selecionadas, verificar a adoção da inovação aberta e descrever a contribuição desta para a vantagem competitiva foram os objetivos específicos. O referencial teórico articula a literatura sobre inovação e vantagem competitiva para melhor entendimento das inter-relações entre os constructos. Dez organizações, duas associações e um representante da academia foram selecionados após análise de informações institucionais e registros documentais. Os principais executivos das empresas nacionais, multinacionais e associações de fabricantes responderam à pesquisa com perguntas semiestruturadas, roteiro padrão e perguntas abertas. O tratamento dos dados qualitativos seguiu a técnica de análise interpretativa. As metacategorias encontradas foram: inovação, pesquisa e desenvolvimento, inovação aberta e vantagem competitiva. Os resultados sinalizam que nestas empresas os produtos novos decorrem de inovações incrementais, radicais e disruptivas. Elas utilizam estratégias tecnológicas ofensivas, defensivas, imitativas e dependentes. No Brasil, a prática da inovação aberta entre as indústrias nacionais participantes acontece em diferentes estágios, conforme gestão interna e externa dos processos de inovação, propriedade intelectual, parcerias, pesquisa e desenvolvimento. Indústrias multinacionais que praticam a inovação aberta no exterior, não adotam no Brasil por razões que coincidem entre os entrevistados. Empresas que utilizam a inovação aberta relataram sua contribuição para recursos e capacidades valiosos, raros e inimitáveis. Dificuldades para adoção no país, também foram mencionadas. Espera-se que este estudo contribua para futuros trabalhos e pesquisas acadêmicas relacionadas à inovação aberta.

APA, Harvard, Vancouver, ISO, and other styles

25

Ventura, João Diogo Livreiro. "Equity research - Pfizer Inc." Master's thesis, Instituto Superior de Economia e Gestão, 2021. http://hdl.handle.net/10400.5/23396.

Full text

Abstract:

Mestrado Bolonha em Finanças
This report includes a detailed valuation of Pfizer Inc. The format of this Equity Research Report combines both rules of ISEG Master Final Work Project and the CFA institute recommendations. The choice of Pfizer Inc was firstly because the pharmaceutical industry is a trending topic nowadays, due to covid-19, and secondly because Pfizer developed the first covid-19 vaccine which awakened in me a special interest in learning more about the company. Pfizer Inc. (PFE) is a research-based, global biopharmaceutical company, that is committed to the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide – with 2020FY revenues of $41.9Bn and a market capitalization of $205 Bn. Pfizer has a BUY recommendation, with a 2022FY PT of $54.48/share, which represents an upside potential of 18.3%, equivalent to an annualized return of 13.4%, against the closing price of $46.07/share on August 31st, 2021, with medium risk. The PT was obtained using Discounted Cash Flow model (DCF), other methodologies were considered to reach Pfizer’s PT such as the Adjusted Present Value (APV), the Flow-to-Equity (FTE) method, the Dividend Discount Model (DDM), and a Relative Valuation using market multiples from peers. The report also includes a detailed explanation about the risks that can affect the price target, as well as a sensitivity analysis to assess the impact of those risks in the investment recommendation. This report considers all the public information available until 31st August 2021.
Este relatório inclui uma avaliação detalhada da Pfizer Inc. O formato desta Equity Research combina as regras do Projeto de Trabalho Final de Mestrado do ISEG e as recomendações do CFA Institute. A escolha da Pfizer Inc foi em primeiro lugar devido à indústria farmacêutica ser uma indústria que está na moda hoje em dia, devido à pandemia de covid-19, e em segundo lugar porque a Pfizer foi a empresa que desenvolveu a primeira vacina, o que despertou em mim um interesse especial em aprender mais sobre a empresa. A Pfizer Inc. (PFE) é uma empresa farmacêutica que opera a nível global dedicando-se à pesquisa, descoberta, desenvolvimento, produção, marketing, vendas e distribuição de produtos farmacêuticos em todo o mundo - com uma receita no final do ano de 2020 de 41,9 mil milhões de dólares e uma capitalização de mercado de 205 mil milhões de dólares. A Pfizer tem uma recomendação de COMPRA, com um preço alvo de $ 54,48/ação para o final do ano de 2022, o que representa uma potencial valorização de 18,3%, equivalente a um retorno anualizado de 13,4%, contra o preço de fecho de $ 46,07/ação em 31 de agosto de 2021, com risco médio. O preço alvo foi obtido usando o modelo dos Fluxos de Caixa Descontados (DCF), outras metodologias foram consideradas para calcular o preço alvo da Pfizer, como o Valor Presente Ajustado (APV), o método Flow-to-Equity (FTE), o Modelo de Dividendos Descontados (DDM) e uma Avaliação Relativa usando múltiplos de mercado de empresas comparáveis. O relatório também inclui uma explicação detalhada sobre os riscos que podem afetar o preço alvo bem como uma análise de sensibilidade para quantificar o impacto desses riscos na recomendação. Para este relatório foram consideradas todas as informações públicas disponíveis até 31 de agosto de 2021.
info:eu-repo/semantics/publishedVersion

APA, Harvard, Vancouver, ISO, and other styles

26

鮑菲飛. "基於部門創新理論的中國生物製藥產業發展分析." Thesis, University of Macau, 2011. http://umaclib3.umac.mo/record=b2525099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Chen, Yu-Fang, and 陳禹芳. "A Study On Industrial Clusters Of Pharmaceutical Industry/ Biotechnology Industry." Thesis, 2005. http://ndltd.ncl.edu.tw/handle/26767943271526428102.

Full text

Abstract:

碩士
國立成功大學
都市計劃學系碩博士班
93
In 1990 Porter brought up the conception that industrial cluster is closely linked with industrial competition, it has arouse highly attention of academe, also a lot of developed countries took this appearance of assemblage policy as the development policy for their industries. Presently, through the experience from foreign countries which try to develop the ripe biotech industries and related enterprises, we can realize that the key element of succeeded development is perfectly utilizing the effects of industrial cluster. For this reason, facing the advantageous position from globalization and foreign firms/enterprises, how to consolidate domestic firm’s competition and to promote the whole industrial environment are the current major issues. 　Mainly, this study tries to use the related views of industrial cluster to be my theory foundation. On the one hand, I try to collect the related domestic industrial policy and the profile of Taiwan’s Science Park; On the other hand, I also use expert interview and questionnaire survey which adopt the network concept and the characteristic of spatial distribution to observe the relationship between pharmaceutical industry/biotechnology industry and supplier/customer industry. Hence, I can draw the map which describes the character of biotech industrial cluster, and from my empirical case I also review the related industrial policies in order to bring up my suggestions which related to the spatial development of pharmaceutical industry and biotechnology industry.

APA, Harvard, Vancouver, ISO, and other styles

28

TSAI, CHIA-CHUN, and 蔡佳純. "An Application of Real Option to Pharmaceutical Biotechnology Industry." Thesis, 2003. http://ndltd.ncl.edu.tw/handle/61792328454256527223.

Full text

Abstract:

碩士
國立臺灣科技大學
企業管理系
91
A great deal of effort has been made on real option pricing. What seems to be lacking, however, is an application with numbers for executives to value whole projects to their industry. The pharmaceutical biotechnology industry is a high-return combined high uncertainty industry, in which, companies must have significant valuations long before they earn any profits from selling their products. There is a general agreement that using a real option pricing theory will catch the flexibility value in this kind of industry. This paper is intended as a valuation to whole new-drug development project by Merton’s jump diffusion model and binomial method. We use the characteristics of successful probability in new-drug development process to divide the option pricing into two stages.

APA, Harvard, Vancouver, ISO, and other styles

29

Hsiao, Chan, and 蕭蟬. "The Development Patterns of Biotechnology Pharmaceutical Industry in Taiwan." Thesis, 2002. http://ndltd.ncl.edu.tw/handle/74362621804120654460.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chiang, Yi-Lin, and 江依霖. "The Study of Applying Biotechnology in Pharmaceutical Industry in Taiwan." Thesis, 2001. http://ndltd.ncl.edu.tw/handle/57984738877271805068.

Full text

Abstract:

碩士
國立臺灣大學
國際企業學研究所
89
Abstract Recent discoveries in biotechnology are propelling exciting and revolutionary advances in pharmaceutical industry especially in the research and development process. This research aims to study the competitive analysis of applying biotechnology in pharmaceutical industry following the “Diamond Model” proposed by Michael Porter in The Competitive Advantage of Nations. Chapter Four and Five will devote in presenting the current conditions of biotechnology and pharmaceutical industries respectively including their characteristics and market developments. Lastly, Chapter Six will focus on the application analysis of biotechnology in pharmaceutical industry in Taiwan. First, this research has revealed that both the domestic and global demands on bio-pharmaceutical products are great, but the small domestic market can not support the economies of scale of the heavy R&D operation characteristic of this industry. Second, opportunities in bio-pharmaceuticals have emerged with FDA lessening on the approval regulations on botanical drug products and expiration of drug patents, but Taiwan is either unable or slow to capitalize on these opportunities. Third, the domestic abilities in fundamental R&D as well as the quality of human resources can support the down-stream operations of pharmaceutical industry but weak in the pioneering and innovative technology research. Also, biotechnology and pharmaceutical industries are asserting “pulling effect” on each other but venture capital firms assume an important role in providing the initial funding to start-ups enterprises. In addition, although the lack of intense domestic rivals can’t drive the development and innovation in domestic bio-pharmaceutical industry, most domestic companies have followed the global trends and sought international strategic partners. Lastly, with the government support the risk in investing in domestic bio-pharmaceutical industry is greatly reduced. In conclusion, since applying biotechnology in pharmaceutical industry can reduce production time and cost while increasing the quality and efficiency, biotechnology revolutionizes the drug formulation process and broadens the scope of drug targets. Biotechnology can not only increase the competitiveness of our pharmaceutical industry but also capture the great potential brought about by this disruptive technology. This global trend creates new demands both domestically and globally. Since this industry does not emphasize on vertical integration but rather on division of labor, globally competitive strategic partners are crucial for survival. Most importantly, more capital resources and efforts still must be devoted into promoting and developing this industry and improving the domestic environment conditions.

APA, Harvard, Vancouver, ISO, and other styles

31

Dando, Malcolm R. "The Strengthened BTWC Protocol: Implications for the Biotechnology and Pharmaceutical Industry." 1998. http://hdl.handle.net/10454/765.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

LIN, JENG YU, and 林政宇. "Performance Evaluation of Biotechnology Pharmaceutical Industry in Taiwan using Data Envelopment Analysis." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/75122825505227390356.

Full text

Abstract:

碩士
大葉大學
工業工程與科技管理學系
97
The biotechnology industry is a star industry that the world is focusing in 21th century, and The Ministry of Economic Affairs in Taiwan has already considered the biotechnology industry is one of the binary star industry in “Two Trillion and Twin Star Industries Development Plan” as well. The biotechnology industry includes three types: biotechnology pharmaceutical industry, biotechnology medical device industry and newly arisen biotechnology industry. The sales amount of biotechnology pharmaceutical industry has contributed the most of the total sales amount of biotechnology industry by 2005. This sales amount was surpassed by that of biotechnology medical device industry until 2006. Thus, this research uses Data Envelopment Analysis(DEA) to perform evaluation of biotechnology pharmaceutical industry. In the evaluation process, a two-stage DEA was failed because the pre-assumptions are wrong. Actually, the assumption of considering makes a mistake. The patent effect of making profits is postponed in practices. The scores of decision marking unit(DMU) was fluctuated by environment in the proposed fuzzy multi-objective data envelopment analysis. In addition, in the slack variable analysis, it shows that nearly 50% of the DMUs have the tendency to over-invest. And in the sensitivity analysis, the threshold h the efficiency value has no influences on the computed results. Finally, the discrimination power of the fuzzy multi-objective DEA is better than that of traditional DEA.

APA, Harvard, Vancouver, ISO, and other styles

33

Chen, Ying-Ching, and 陳櫻青. "A Study on the Operational Performance of Biotechnology Pharmaceutical Industry in Taiwan." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/87274174904465423503.

Full text

Abstract:

碩士
健行科技大學
國際企業管理研究所
102
As of January 4, 2013, the U.S. Census Bureau had estimated that the population of world had approached to 7.057 billion. These people inevitably require biomedical treatment when they get sick or get old during their lifetimes. Similarly, we are facing an aging population and low birth rate in Taiwan. Moreover, there are frequent outbreaks of mutated infectious disease. Therefore, biotechnology industry is getting more and more important and the output value of biotechnology industry in future should not be underestimated. At present, the biotechnology industry in Taiwan includes pharmaceutical industry, medical equipment industry and emerging biotechnology industry. This study focuses on biopharmaceutical industry as the research object. The characteristics of biopharmaceutical industry are long-term R&D, high barriers to enter, long-life products, unaffected by economic recession and regardless of nationality or season. However, whether the manufacturers can exist or not in the fierce global competition among biopharmaceutical industry depends on the operational performance of manufacturers. Having a good operational performance, the corporation can be in sustainable development. Therefore, we chose biotech pharmaceutical companies in Taiwan as samples for this study. The performance evaluative variables of the study include number of employees, total assets and research & development expenses as input variables, net operating income and pre-tax net income as output variable. The financial information of biotech pharmaceutical manufacturers in 2011 and 2012 was retrieved from database of Taiwan Economic Journal (TEJ). Then, we evaluated the operational performance of biotech pharmaceutical manufacturers in Taiwan by CCR and BCC DEA-models (Data Envelopment Analysis, DEA). We could figure out whether the production situation of biotech pharmaceutical manufacturers has reached optimal allocation of resources from the analysis. The empirical results could provide biotech pharmaceutical companies as references.

APA, Harvard, Vancouver, ISO, and other styles

34

Lee, Feng-Chen, and 李逢春. "Present Situation and Competitive Strategy of Taiwan Pharmaceutical Industry Under Way of Biotechnology." Thesis, 2003. http://ndltd.ncl.edu.tw/handle/94552255259691079980.

Full text

Abstract:

碩士
元智大學
管理研究所
91
Human Genome Project, led by National Human Genome Research Institute of US government, an international research project to draft map of each human gene, had completed sequence human DNA in 2000. The Biotech firm of Celera Genomic announced its success on the sequence human DNA as well. In April 2003, the International Human Genome Sequencing Consortium is announcing an essentially finished version of the human genome sequence that brings up terrific prospects to biological technology industry for the future. Biological technology industry has shown great potential capability in its only 30 years history. People expect that an evolving technique of biological technology used to treat inherited diseases and benefit those who are gene disorders. After draft of the human genome map is completed, the new drug research and development model has been changed in the Pharmaceutical industry which is highly related to biological technology, In the traditional way to develop new drug is to use the technology of chemical component to develop lead drug for innovating more effective of new drug. Due to effectiveness of lead drug can’t be absolutely validated; it is necessary to implement pre-clinical study for ensure lead drug effectiveness and safety. By this way of try and error, scientists can explore the lead drug firstly and then verify its target. The completion of human gene map provides new model of new drug research and development. Scientist use more than 50,000 of targets to explore and develop new drug according to logical sequence to explore the cause of disease and then develop the lead drug as required. New model will reduce time of new drug R&D. The pharmaceutical industry is the core of biological technology. While, pharmaceutical market scale in Taiwan is quite small; it is limited in the competitive domestic market. Highly depends on biological technology of pharmaceutical industry is not well organized, lack of research and development capability, animal test, clinical research and study, incompletion of drug monument regulation. However, there are some firms in Taiwan have successfully built up its competitive advantage and develop its products on the niche market. This research report is on the basis of the biotechnology industrial related benchmark of multinational pharmaceutical business model to explore its key successful factors with cases study. From 6 dimensions of characters of biological technology, intellectual property strategic management, research and development of innovation, national innovation system, collaborative alliance between new biological firm and existing pharmaceutical corporate, and government policy analysis its competitive situation. This report attempt to find out competitive strategies for local pharmaceutical firms, and provide the proposal of business strategies.

APA, Harvard, Vancouver, ISO, and other styles

35

Wang, Hsing-Hung, and 王興弘. "The Developing Pattern of Pharmaceutical Industry -- The Cooperation and Competition between Multinational Pharmaceutical Group and Emerging Biotechnology Company." Thesis, 2006. http://ndltd.ncl.edu.tw/handle/18767267486547516631.

Full text

Abstract:

碩士
國立臺灣大學
商學研究所
94
The development of biotechnology could be traced back in 1970s and it started from small size institution with research-based competency. Till now, the developing business scale of total biotech companies even competes with the business of multinational pharmaceutical companies. The biotechnology has become a concrete growth driver within pharmaceutical industry; meantime, the multinational pharmaceutical companies are suffered from the patents expiration of major products and bothered with the lag behind of new drug launch. Due to the methodology of biotech is differ from traditional pattern to develop new drugs or modify existing ones, the biotechnology provides a more precise and more efficient way in disease treatment and prevention. The innovative approach from the biotech companies timely releases the tension of some multinational pharmaceutical companies in poor product portfolio. The strong growth of the biotechnology companies provides a solution from Big Pharma''s struggling and also recognizes a mainstream in current pharmaceutical industry development. The objective of the thesis will focus on introducing the cooperation and competition within two major players - the traditional pharmaceutical company and the emerging biotechnology company. The thesis will cover the feature analysis of pharmaceutical industry. It includes the topics as follows, 1. Long R&D period and highly regulated by government policy 2. Huge investment behind high risk and high profit return 3. Meticulous vertical integration and long-extended industry value chain In order to react the higher threshold in drug development and defense the market share erosion due to the generics penetrate into major disease market, the multinational pharmaceutical companies face the critical challenge of margin lose and struggling for survival. Attribute to the fast development of biotechnology and niche market growth like cancer, rare disease…etc.) After suffer the merger and acquirement in 1990s, the multinational pharmaceutical groups and biotech venture capitals heavy invested in the emerging biotechnology institutions / companies to trigger a new trend of integration within pharmaceutical industry. This wave of industry reorganization will involve the traditional pharmaceutical companies, biotechnology companies and regional generics companies especially. Expect to share the finding with peoples who are interested in the most important industry of the twenty-first century.

APA, Harvard, Vancouver, ISO, and other styles

36

Wang, Chien-Shun, and 王建順. "Research Channel Conflict between Agents and DistributorsPartnerships - Taking the Pharmaceutical Biotechnology Industry for Example." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/4844ut.

Full text

Abstract:

碩士
高苑科技大學
經營管理研究所
102
This study discuss respectively what are cognitive conflict factors for "agent and dealer" in channel cooperation on cognitive dissonance theory and Opportunism. This study we collect and investigate related literatures by Delphi Technique and The analytic hierarchy process to propose how the decision-making model to response and manage conflicts among distributor partners. The study adopts paired questionnaire survey manner and we invite national pharmaceutical biotech industry executives working experience over a decade including experts to join the questionnaires. We sent 40 copies questionnaire that the agents get questionnaire 20 parts and the dealers get the others. These pharmaceutical biotech industry executives with more than 10 years of experience have deep insights and learnings about Price-cutting competition between the agents and the dealers. According to the questionnaire results they do shows the stand of agents and distributors and approaches the actual situation. The study questionnaires were sent to subjects in ROC 102 years on June 24 and delivered back in ROC 102 years on July 10. The numbers of sent and received back questionnaires are the same, a total of 40 questionnaires. The valid return rate was 100%. The study indicate that facing the channel conflict factor of "agent and dealer" cooperation relationship, the cognitive style plays the most selected cause and relationship costs followed when exploring factors such as cognitive style, relationship costs and Tension against. Among the top five the key selections criteria are relations burden, sales expectations, communication issues, trust disturbance, operational strategy. The less decisive indicators are cooperation crisis and resource requirements.

APA, Harvard, Vancouver, ISO, and other styles

37

Chuang, Chin-Fong, and 莊金鳳. "Marketing Strategy Biotechnology Pharmaceutical Industry Production Equipment Dealers – A Case Study on S Company." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/zqtmy2.

Full text

Abstract:

碩士
淡江大學
國際企業學系碩士在職專班
104
In this study, to Taiwan''s industrial structure and development trend of the medical technology in recent years, governments across the world will be the development of the biotech industry as an important national development goal, and Taiwan also plays an important role in this milestone, and has by law to promote and strengthen the biotechnology industry could flourish. In the situation of many businesses opportunities, how can we use complete marketing strategy to create more profits, so that enterprises can sustainable development. In this study, companies in the S objects to study the formation of S company business competitive strategy, using Lin and Pao (2004) proposed policy evaluation frame, through the company''s mission statement cases to 7S model for internal environmental assessment to the five forces model analysis of the industry environment and the use of the opportunities and threats PESTEL architecture overall assessment of their environmental impact, through internal environment, external environment for the whole industry and the overall analysis, investigate cases of agents forming elements of the marketing strategy, and how to perform and then reached the corporate mission. S companies in Taiwan biomedical agents, the agents how to face the rapidly changing and complex nature, the development of unique marketing strategy needs to be applied because of the market, by the most appropriate positive "policy expertise and exclusive agent" in execution to achieve "a technology leader in biotechnology pharmaceutical industry" under the mission statement Company S, a Taiwan biomedical agent, how to face the rapidly changing and complex nature to develop unique marketing strategy for needs of the market, by the most appropriate positive "policy expertise and exclusive agent" in execution to achieve "a technology leader in biotechnology pharmaceutical industry" under the mission statement.

APA, Harvard, Vancouver, ISO, and other styles

38

liu, Chih hung, and 劉之鈜. "A Competitive Edge Study of Taiwan’s Biotechnology Pharmaceutical Manufacturing Industry in Entering Health Food Market." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/94564529989441396828.

Full text

Abstract:

碩士
長庚大學
企業管理研究所
97
Abstract There are two main factors limiting Taiwan’s biotechnology Pharmaceutical Manufacturing Industry. Firstly, the industry faces the challenge on R&D investment and new product development. Secondly, the industry encounters many uncertainties. With the increasing awareness of personal health, more and more people are paying attention to healthy foods market.This trend contributes to the increasing investment from entrepreneurs on health food products, and it accentuates the strengths of the biotechnology Pharmaceutical industry. This research is accomplished by applying an in-depth interview approach to establish the requirements for the people to interview. It is also a way to capture the respondents’ thoughts through Q&A sessions. The objectives are to obtain valuable information from the interviews and use that to foresee the industry outlook and identify potential solutions to problems the industry may encounter. Due to the close relationship it has with the prestigious medical and pharmaceutical industries, Biotechnology Pharmaceutical manufacturing industry receives similar recognition. In addition, the industry possesses strong product development capabilities to help enhance the product quality of the health foods market. Since the biotechnology Pharmaceutical manufacturing industry promotes competitive advantages, enters prosperous markets, and utilizes industrial strengths. Therefore, the market is becoming one of the biotechnology Pharmaceutical manufacturing industry’s strategic development areas.

APA, Harvard, Vancouver, ISO, and other styles

39

Lin, Yin-Chun, and 林吟純. "The Determinants of Patent Diversification：An Empirical Study of U.S. Biotechnology, Pharmaceutical, and Medical Instrument Industry." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/36063505948497780814.

Full text

Abstract:

碩士
逢甲大學
企業管理所
98
In the era of knowledge economy, firm can improve overall competitive advantage by R&D and continually innovation. To achieve target of maximal profit and sustainable development, enterprises not only from the patent to understand the current competitive position in the industry, but also implement diversify strategies to maintain the existing business’s growth. The purpose of this study is to analyze and explore the determinants of patent diversification in U.S. Biological, Pharmaceutical, and Medical Instrument Industries. The observation time is from 2003 to 2008 and the data set include 216 Biological observations, 296 Pharmaceutical observations and 182 Medical Instrument observations in the United States Patent and Trademark Office (USPTO) database. We used the multinomial logistic regression to extract the determining factors of patent citations. This study includes 7 factors of affecting patent diversification: R&D intensity, capital expenditures, firm sizes, firm risk, firm age, diversification, and patent positions. We find that firm age and patent positions are significant in the Biological industry. Firm sizes and diversification are significant in the Pharmaceutical industry. Capital expenditures, firm sizes, diversification, and patent positions are significant in the Medical Instrument industry. Firms can use capital expenditures, firm sizes, firm age, diversification and patent positions to improve patent diversification.

APA, Harvard, Vancouver, ISO, and other styles

40

Yang, Ying-huan, and 楊英煥. "Use Actor-Network Theory for R&D Performance The Case of Biotechnology Pharmaceutical Industry." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/76694935231922403397.

Full text

Abstract:

碩士
國立中央大學
企業管理學系
101
Biotechnology industry is technology-intensive, highly innovative and high value-added industries. Especially in the pharmaceutical industry. Because biotech products subject to regulatory control. Resulting in long product development, funds raised is not easy because high investment risk. Difficult for many businesses to support to the stage to market, so efficient R&D performance is important foundation of the development of the biotechnology pharmaceutical industry. The other hand, the U.S. biotech industry become the industry leader because a steady stream of innovative technologies from academic and research institutions spread to the industry. The formation of social and technological interwoven network relationships in Scientists and industry. Therefore, this study applied the concept of Actor-Network Theory(ANT), the formation of a heterogeneous network in actor interessment, knowledge translation, situational conversion. Explore how to improve the biotechnology industries’ R&D performance by network cooperation. Although researchers have used multi-stage DEA and variables to measure R&D performance in the past, but they ignores the network concept into R&D performance evaluation studies. Therefore, this study establishes R&D performance model by situational conversion of biotechnology industry in Actor-Network Theory and network DEA -technology creation capability, technology diffusion capability and value creation capability, and analyze R&D performance of 22 biotechnology pharmaceutical corporations in Taiwan. The study finds the overall Taiwanese pharmaceutical industries’ R&D performance should be improved. Technology creation capability shows insufficient domestic patent. The technical cooperation group is more efficient than independent development in benchmarking. It shows R&D performance can be improved by Network cooperation. This study suggests that biotechnology industries create obligatory passage point(OPP) in ANT by industry-academic-government heterogeneous network collaboration and industry clusters. specialization and division of labor establish value chain can not only reduce the risk of operation and R&D but also step up industry scale and R&D performance.

APA, Harvard, Vancouver, ISO, and other styles

41

"Market Orientation, Alliance Orientation, and Business Performance in the Canadian Biotechnology Industry." Thesis, 2013. http://hdl.handle.net/10388/ETD-2013-03-951.

Full text

Abstract:

There is a large body of research supporting the importance of market orientation in determining performance. A growing body of research supports the notion that strategic alliance management competencies positively influence performance. Few empirical investigations have examined the importance of market orientation in the biotechnology industry, much less the effect of alliance orientation on performance, or the combined effect of market and alliance orientation on performance. This study explores these relationships among Canadian biotechnology companies with medical/healthcare focuses. Of the 394 Canadian medical/healthcare biotechnology companies identified, 81 usable responses were received, yielding a response rate of 20.6 percent. It was found that market orientation positively and significantly influenced business performance, supporting the first hypothesis. Additionally, alliance orientation positively and significantly influenced business performance, supporting the second hypothesis. However, when market and alliance orientation were examined together, alliance orientation’s effect on business performance remained positive and significant, but market orientation’s effect on business performance became negative and non-significant. This prompted a further analysis that investigated the presence of a mediation relationship. Market orientation was fully mediated by alliance orientation in its relationship with business performance. This study contributes academically by adding to market and alliance orientation research and by the successful development of a biotechnology-specific performance instrument. This study contributes to marketing and management strategy, as it outlines performance indicators that enable high performance.

APA, Harvard, Vancouver, ISO, and other styles

42

Lung, Tan-Ke, and 龍談格. "The Investigation of the important factors of influencing pharmaceutical biotechnology academia-industry cooperation〜Innovation diffusion theory." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/xr95fp.

Full text

Abstract:

碩士
中國醫藥大學
醫務管理學系碩士在職專班
101
Background and Purpose: With the global aging health and home care arising from problems of chronic disease increases, personalized health care and preventive medical care and other factors make the rise of governments to develop policies to promote the pharmaceutical and biotech industry through academia-industry cooperation to enhance competitiveness. Our government has long invested heavily in biotechnology and human development of pharmaceutical academia-industry cooperation, at this stage of the global market share is still less than 1%, indicating that Our government investment in pharmaceutical biotechnology-related academic institutes accumulated long-term R & D capabilities and can not spread to the industry by downstream firms to undertake and successfully applied to create the expected value of the specific academia-industry cooperation. The purpose of this study is to investizate innovation diffusion theory (innovation body, communication channels, time and social system) for teachers and industries to participate influence willingness in the pharmaceutical biotechnology academia-industry cooperation.According to the findings and recommendations to provide industry-academia cooperation in promoting future reference. Methods: The study is cross-sectional survey by industry and academia expert validity testing of the questionnaire, the central medical University of full-time teachers and related industries, a total of 1500 questionnaires (teacher 500 questionnaires were returned 122, the responding rate =24.4%; industry 1000 questionnaires were returned 314, the responding rate = 31.4%). Valid questionnaires were recovered and finished with SPSS 18.0 and Amos 6.0 for data archiving and analysis, and descriptive statistics, factor analysis, reliability analysis, confirmatory factor analysis,and binary logistic regression statistical methods to investizate influencing pharmaceutical biotechnology academia-industry cooperation the important factors. Results: Influencing academic teachers to participate in pharmaceutica biotechnology academia-industry cooperation willingness analysis are: "communication channels" (β = 0.188, p = 0.046) and "Time" (β = 0.373, p = 0.018) two factors reach statistical significant; Influencing industry vendors to participate pharmaceutical biotechnology academia-industry cooperation willingness analysis are: "communication channels" (β = 0.373, p = 0.018) and "Time" (β = 0.668, p = 0.034) as well as "social system" (β = 0.049, p = 0.041) three factors reach statistical significant. Another characteristic variables of the organization "whether the R & D units" (β = -1.153, p = 0.001) for the diffusion of innovation in academia-industry cooperation statistically significant sense, that "none" of their participation in corporate R & D units academia-industry cooperation willingness to tendency than "yes" corporate R & D units is high. Conclusions and Recommendations: Pharmaceutical Biotech the important factors in the development of academia-industry cooperation in addition to the technical field of its own subjects, the other in the communication channels, time and social system are also important factors. This study suggests that government should be relaxed medicine policies and regulations, the academia should build pharmaceutical biotech academia-industry cooperation in the management, evaluation platform, the industry should be encouraged to invest in innovation and research and development, in order to build academia-official-industry pharmaceutical biotechnology industry.

APA, Harvard, Vancouver, ISO, and other styles

43

Hung, Tze Chiu, and 洪子秋. "A study on the commercialization of the intellectual property of biotechnology and pharmaceutical industry--Regulatory perspective." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/35741829672770100850.

Full text

Abstract:

碩士
國立政治大學
智慧財產研究所
98
In recent years, we have already developed some achievements in biotech researches in Taiwan and are in a leading position in Asia under the efforts of government and industries. However, these technologies still are slowly developed to the commercialized phase. Thus, the achievement of these researches does not benefit industry substantially. In the process of commercialization of biotech research, we have to consider all the aspects, including technology and regulation, intellectual property, finance and management. With a well-rounded development plan, technologies in the bud will gradually develop to a mature commodity, and earn fiscal profit in the market. The profit will consequently contribute to research activity. A virtuous circle will be formed. The strategies of commercialization differ considerably among industries. Regarding biopharmaceutical industry which has the properties of highly regulated by competent authorities, time consuming, heavy capital, and global marketing, the regulation assessment is not only complicate but also critical to project implementation. The required documents according by regional authorities will be a decisive factor to consider the development plan including the estimated timetable, needed resources. Due to the regulation system in US affected a lot legislation for laws in Taiwan , America and Taiwan will be the prior topics in this research. A well-developed legal framework and protection of intellectual property rights is the prerequisite for building an ideal environment where the biotechnology and pharmaceutical industries can flourish. In order to improve the environment for these industries, in recent years the government has approved the amendment and execution of related laws and regulations. Amendments have been made to related tax benefit and incentive measures of investment. Other amendments have been made which have allowed R&D results to be more easily transferred to academia and industry. Looking into the future, under the joint cooperation of industry, academia and research institutes, and with the government’s policy to fully promote the sector, it is believed that Taiwan will have well developed in the near future.

APA, Harvard, Vancouver, ISO, and other styles

44

Chuang, Fu-Chia, and 莊馥嘉. "A Study on Vaccine Patent Protection and Battle Strategy for Biotechnology Companies and the Pharmaceutical Industry." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/63449102910919779333.

Full text

Abstract:

碩士
臺灣大學
科際整合法律學研究所
98
The purpose of this thesis is to provide a set of patent and battle strategies for the domestic pharmaceutical industry and biotechnology companies. The aim is to obtain a comprehensive protection of vaccine-related technology. The thesis is divided into four parts: the concept of vaccine, the current development of the vaccine market and the vaccine patents, patent law and finally the vaccine protection strategies before and during the period of patent right. Part I talks about how a vaccine works and how to manufacture vaccines, as well as how much time and money would be consumed during the whole process from the laboratory stage to the point where it is possible to apply the vaccine to human beings and be released onto the market. According to this study, it is evident that it is a long and difficult way for a single vaccine to become a final product, and it needs the combination of both business and patent protection strategies to support this process. This is because a correct patent strategy gives correct direction for the development and protection of research results, which then leads to successful development and marketing. Successful marketing, on the other hand, provides funds for the development and successful development brings good business. Therefore, these three elements -- development, marketing and patent strategy -- work together in a complementary fashion. Accordingly, Part II takes the perspective of the current market, to understand the development trend of the vaccine technology and the market distribution of vaccine products, as well as the vaccine-related patent applications. Part III then discusses the patent law. Part IV is further divided into three parts: the technology protection strategies from the research stage to the market, battle strategies after obtaining patent rights, and collaborations after obtaining patents. Part (i) includes the assessment and management of a technology before filing a patent application and the strategy of obtaining a patent; Part (ii) provides respective strategies for the plaintiff and the defendant in a patent suit; Part (iii) describes different levels of cooperation, from licensing to alliances and M&As.

APA, Harvard, Vancouver, ISO, and other styles

45

Cheng, Po-Yuan, and 鄭博元. "An Empirical Study of Construct Integration Innovative Business Model ─ Case Study of Biotechnology and Pharmaceutical Industry." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/xj74b3.

Full text

Abstract:

碩士
長榮大學
高階管理碩士在職專班
100
There were many categorizing methods and content of dimensional factors of business model, thus this research makes attempts to integrate a systematic “innovation business model” for biotechnology and pharmaceutical industries from home and abroad. First, this research made broad analysis on critical successful factor and structure of business model, to rebuild new factors from distinct viewpoints, and then proposed a structure of “innovation business model” through grounded data of hierarchy analysis and in-depth interview. The structure could be categorized into five main dimensions: “strategy selection”, “value chain”, “value creation”, “value grasping” and “environmental factors”, in addition to 10 minor dimensional factors. The permanent dynamic changes and interaction was the source of continuous innovation, in which the 10 minor dimensional factors were core resources, value statement and customer relationship, differentiation, information orientation, service orientation, social culture, technical factor, cost and profit. These minor factors were action and results in practice, combination of these minor factors with core main dimensions would be the concrete content of systematic “innovative business model.”

APA, Harvard, Vancouver, ISO, and other styles

46

Dai, Janet, and 戴蕙敏. "The Influence of Resource, Capability and Social Capital on Operating Performance: Evidence from Taiwanese Biotechnology & Pharmaceutical Industry." Thesis, 2005. http://ndltd.ncl.edu.tw/handle/66036217673485106481.

Full text

Abstract:

碩士
輔仁大學
科技管理學程碩士在職專班
93
Due to the needs of larger investments, higher R&D risks, expenses and longer development period, Biotech industry in Taiwan still is in its germinating stage. However, studies from US biotech evolution since 1975 demonstrate resource & capability from inside the company combines with social capital from outside the company, those financial operating performance indicators, as well as crew unity and innovation speed, those non-financial indicators are the important factors that could improve a company’s sales or profit margin. From previously researches on biotech industrial operating performance, we found more attentions were focused on industry structure and invention strategy, instead of on the resource & capability inside the company, and social capital outside. Abundant resources could support R&D activities and maintain company operating. Strong capability could keep innovation continuing and create competitive advantage. Social capital could help company to get innovative technologies increasing its performance by communicating with other related organizations. In this study, therefore, we have chosen social capital, resource & capability as our effect factors to study their influence in Taiwan biotech industry operating performance. Most of the Taiwan Biotech companies are in the early developing stage. Their business strategies, R&D programs and progresses are completely different resulting hard to define performance. In this case, AHP has been chosen as our study tool to systematically get those critical factors that affect the operating performance of Taiwan biotechs from those unknown and complex situations. Concluded from 11 effective questionnaires, several identical and valid results are observed: 1. Both personnel and organization capabilities are the crucial factors for operating performance. Particularly, organization learning could arouse innovation, speed up R&D, in results, and enforce company competition. 2. Intangible resource is the key factor that could speed up return of investment in a relatively short time period when compares with tangible resource. 3. Among all kind of social capitals, linking social capital is the most important one to influence operating performance, and this is because Taiwan biotechs strongly need government supports in their beginning stage. According to the results from our studies, we recommend Taiwan biotech companies could take following suggestions to improve their operating performance: 1. Build R&D data bank to strengthen technology innovation and commercialization capability. 2. Implement patent application, and demand using lab book to document all R&D activities to legally protect business secrets. 3. Recruit professionals with great industry experiences, and hold internal training courses to interflow knowledge. 4. Focus on linking social capital, and have special unit in charging communication with government, as well as related societies, associations and organizations.

APA, Harvard, Vancouver, ISO, and other styles

47

Tai, Ting-Feng, and 戴庭峯. "The effect of Information Asymmetry and R&;D on Corporate Value－The study of Pharmaceutical and Biotechnology Industry." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/x8j6ha.

Full text

Abstract:

碩士
國立高雄第一科技大學
金融系碩士班金融組
102
This paper investigates the effect of information asymmetry and R&;D on corporate value. Using a sample of 12 Pharmaceutical and Biotechnology firms from Taiwan during the period from 2009 to 2013. We find that there is a negative relationship between information asymmetry and corporate value. However, there is a positive relationship between R&;D and corporate value. In addition, in a low degree of information asymmetry, the effect of R&;D intensity is higher than the one of the high degree of information asymmetry on corporate value.

APA, Harvard, Vancouver, ISO, and other styles

48

Tsu-TaiYang and 楊礎黛. "The Effect of R＆D Expenditure and Capital Expenditure on corporate performance in Taiwan's Biotechnology Medical Industry - The Case of Nang Kuang Pharmaceutical Co., Ltd." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/3zzjs8.

Full text

Abstract:

碩士
國立成功大學
財務金融研究所碩士在職專班
104
The objective was to study the effect of R＆D expenditure and capital expenditure on corporate performance in Taiwan's biotechnology medical industry. In this study, the qualitative method - case study was adopted. Before performing case-depth interviews to this company, the history and relative background of the company were understood from secondary literatures in order to prepare the interview outline. Through case-depth interviews, I looked forward to summarizing the conclusions and recommendations by the combination of interview results and literature studies. It is a fact in accountancy that there is a lack of the directly causal relation between the R＆D expenditure and the future income. Additionally, it has a more effect on net profit for a company if current expenses including R＆D expenditure, however, in capital expenditures, it has a less effect on net profit due to the evaluation by an economic amortization. The conclusions of this study are the followings: (1) R＆D expenditure or capital expenditure is a positive effect on corporate performance in Taiwanese biotechnology medical industry. (2) R＆D expenditure has a more positive effect on the stock than capital expenditure. (3) The investment in human resources has a positive effect on corporate performance. (4) R＆D expenditure (intangible assets) is more important than capital expenditure (tangible assets) in investor’s view. (5) R＆D expenditure and capital expenditure have the complementarity for each other.

APA, Harvard, Vancouver, ISO, and other styles

49

Matos, Manuel João de Almeida Albuquerque Brandão. "Process development and optimization towards the production of a non-antibody scaffold-based biotherapeutic." Master's thesis, 2015. http://hdl.handle.net/10362/50529.

Full text

Abstract:

In a context of “green” biotechnology the tendency is to increase investment in methods that rely on microrganisms for the production of biological compounds. The use of these methodologies, contrary to those that rely on the use of chemical components, translate into a higher sustainability in the economical, social and environmental sectors. The upstream development is deeply connected with the cultivation of microrganisms expressing all kind of recombinant proteins. Regarding this work, special attention was given to a specific type of recombinant protein, nanofitins. Nanofitins are artificial proteins created through the technique of ribosome display which consists in several cycles of selection with the goal of creating a synthetic protein with affinity to a specific target. The objective in this experimental work was to implement a protocol for the production and purification of a nanofitin at a pilot scale. Regarding upstream analysis, different specific growth rates were tested during fed-batch administration on a 30L bioreactor, as well as operation times and small scale growth conditions were optimized. At upstream it was concluded that the use of a specific growth rate of 0,175h-1 during fed-batch is sufficient to maximize the microbial growth and its biomass production, as well as the use of only one resistance antibiotic, ampicillin, managed to optimize these parameters. At the downstream level different conditions were studied, namely the techniques of ion exchange chromatography and hydrophobic interaction. The technique of tangential flow filtration was also tested, showing that the use of this technique with two cutoffs, 30kDa and 5kDa, followed by a cationic exchange chromatography is the combination of techniques which presented higher productivities with higher purity ratio. To fulfill GMP requirements, the remotion of the content of endotoxins in the final product was also assessed. The use of Sartobind STIC nano successfully removed up to 97% of endotoxins content on the final product.
Num contexto de biotecnologia “verde” a tendência em investir em métodos que incorporem microrganismos para produção de compostos biológicos é cada vez maior. O uso destas metodologias, ao contrário de metodologias com métodos químicos, traduzem-se numa maior sustentabilidade a nível económico, social e ambiental. O desenvolvimento do upstream está muito relacionado com o cultivo de microrganismos que expressam proteínas recombinantes. No âmbito deste trabalho foi estudado um tipo específico de proteínas recombinantes chamadas nanofitinas. As nanofitinas tratam-se de proteínas geradas pela técnica de ribosome display onde através de diversos ciclos de seleção consegue-se gerar proteínas sintéticas com afinidade para um target. O objetivo deste trabalho experimental foi de implementar um protocolo de produção e purificação de uma nanofitina à escala piloto. No que diz respeito ao upstream foram testadas diferentes taxas específicas de crescimento durante a administração do fed-batch num bioreactor de 30L, assim como otimização de tempos de operação e condições de cultura à pequena escala foram testados. Foi concluído que o uso de uma taxa específica de crescimento de 0,175h-1 durante o fed-batch permite maximizar o crescimento microbiano e biomassa produzida assim como o uso de apenas um antibiótico de resistência, ampicilina, otimiza estes mesmos parâmetros. No downstream foram estudadas condições que permitissem purificar com sucesso a nanofitina, nomeadamente as técnicas de cromatografia de permuta iónica e interação hidrofóbica. Foi também testada a técnica de filtração tangencial, onde foi concluído que a operação sequencial de dois cutoffs diferentes, 30kDa e 5kDa, seguido da técnica de cromatografia de permuta iónica é a metodologia que apresenta produtividades mais elevadas com maior grau de pureza. Visando atingir parâmetros GMP, foi ainda testada a remoção de endotoxinas do produto final. O uso de uma Sartobind STIC nano mostrou remover com sucesso 97% o conteúdo de endotoxinas no produto final.

APA, Harvard, Vancouver, ISO, and other styles

50

Patrício, Maria Inês Abreu Reis. "Desenvolvimento farmacêutico de um medicamento: área analítica." Master's thesis, 2014. http://hdl.handle.net/10437/6263.

Full text

Abstract:

Orientação: Maria Nubélia Silvestre Bravo ; co-orientação: Tiago Costa Cabral Figueiredo
A formação académica que adquiri em engenharia biotecnológica permitiu-me alcançar conhecimentos, desenvolver capacidades e competências, em diversas áreas científicas que foram potenciadas com a minha experiência profissional. No presente Relatório Profissional será demonstrada a experiência profissional e formação contínua que obtive na área da indústria farmacêutica ao longo destes nove anos de vida profissional. De forma a demonstrar os conhecimentos, capacidades e competências adquiridas com a função que desempenho integrada numa equipa de Desenvolvimento Farmacêutico, serão abordadas as tarefas que realizo nas várias etapas de desenvolvimento de um novo produto farmacêutico. Vai ser relatado o processo efetuado para o desenvolvimento de um medicamento genérico sob a forma farmacêutica de cápsulas com elevada qualidade, de forma a garantir o seu desempenho ao nível da segurança e eficácia terapêutica. Durante o processo de desenvolvimento farmacêutico do medicamento genérico participei na área analítica, nas seguintes etapas: caracterização físico-química da substância ativa, desenvolvimento galénico, desenvolvimento e validação dos métodos analíticos e estudos de estabilidade. As principais metodologias e ensaios que apliquei no cumprimento das várias etapas do processo de desenvolvimento do medicamento, bem como o tipo de ferramentas que utilizei e os resultados que obtive foram descritos neste relatório.
The educational background acquired in biotechnological engineering allowed me to achieve knowledge, develop skills and competencies in various scientific fields that have been enhanced with my professional experience. The present Professional Report will demonstrate the work experience and continuing training that I got in the pharmaceutical industry area over these nine years of professional life. In order to demonstrate the knowledge, skills and competencies acquired through the role that I perform integrated in a Pharmaceutical Development team, will be discuss the tasks that I carry out in the various stages of a new pharmaceutical product development. Will be reported the process performed for a generic drug development in the pharmaceutical form of capsules with high quality, to ensure its performance in terms of therapeutic efficacy and safety. During the generic drug pharmaceutical development I participated in the analytical area, in the following steps: physico-chemical characterization of the active substance, galenic development, development and validation of analytical methods and stability studies. The main methods and tests that I applied to comply the various drug process development stages as well as the kind of tools that I used and the achieved results were described in this report.

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic 'Pharmaceutical biotechnology industry'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles